Arunan Kaliyaperumal
Overview
Explore the profile of Arunan Kaliyaperumal including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
23
Citations
241
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Wen Y, Wang X, Cahya S, Anderson P, Velasquez C, Torres C, et al.
J Immunol Methods
. 2021 Sep;
498:113147.
PMID: 34508774
Immunogenicity is one major challenge to the successful development of biotherapeutics because it could adversely affect PK/PD, safety, and efficacy. Preclinical immunogenicity risk assessment strategies and assays have been developed...
2.
Walsh R, Lannan M, Wen Y, Wang X, Moreland C, Willency J, et al.
MAbs
. 2020 May;
12(1):1764829.
PMID: 32370596
Biologics have the potential to induce an immune response when used therapeutically. A number of assays are currently used preclinically to predict the risk of immunogenicity, but the validation of...
3.
Wen Y, Cahya S, Zeng W, Lin J, Wang X, Liu L, et al.
AAPS J
. 2020 Apr;
22(3):68.
PMID: 32300899
Treatment-emergent antidrug antibodies (TE-ADA) pose a major challenge to the development of biotherapeutics. The antidrug antibody responses are highly orchestrated and involve many types of immune cells and biological processes....
4.
Langley R, Kasichayanula S, Trivedi M, Aras G, Kaliyaperumal A, Yuraszeck T, et al.
J Clin Pharmacol
. 2017 Nov;
58(3):340-346.
PMID: 29106714
Etanercept has been recently approved in the United States for the treatment of moderate to severe plaque psoriasis in patients aged 4-17 years. The objective of this study was to...
5.
Bessette L, Khraishi M, Kivitz A, Kaliyaperumal A, Grantab R, Poulin-Costello M, et al.
Rheumatol Ther
. 2017 Sep;
4(2):391-404.
PMID: 28900875
Introduction: To evaluate the efficacy and safety of etanercept treatment in adult patients with moderate to severe rheumatoid arthritis (RA) who failed to respond (primary failure) or lost a satisfactory...
6.
Mytych D, Hock M, Kroenke M, Jawa V, Kaliyaperumal A, Zhou Y
AAPS J
. 2017 Mar;
19(3):599-602.
PMID: 28247192
With more than 100 therapeutic proteins (TP) approved since the first EMA guidance on immunogenicity in 2007, a vast amount of clinical experience with a variety of therapeutic proteins has...
7.
Belouski S, Born D, Jacques S, Harder B, Reynhardt K, Kaliyaperumal A, et al.
Bioanalysis
. 2016 Aug;
8(17):1845-57.
PMID: 27523191
We recommend the application of a strategically designed step-wise approach to transfer cell-based assays that includes assessing analytical performance (through a fit for purpose validation and/or design of experiment robustness...
8.
Kaur P, Chow V, Zhang N, Moxness M, Kaliyaperumal A, Markus R
Ann Rheum Dis
. 2016 Jul;
76(3):526-533.
PMID: 27466231
Objective: To demonstrate pharmacokinetic (PK) similarity of biosimilar candidate ABP 501 relative to adalimumab reference product from the USA and European Union (EU) and evaluate safety, tolerability and immunogenicity of...
9.
Pan W, Li H, Xiao J, Horner M, Lebrec H, Butz E, et al.
Pharmacol Res Perspect
. 2016 Mar;
3(6):e00199.
PMID: 27022472
Hu714MuXHu is a recombinant chimeric murine-human monoclonal antibody directed against interleukin-15 (IL-15), a proinflammatory cytokine associated with memory CD8+ and natural killer (NK) T-cell activation and implicated in the pathogenesis...
10.
Stohl W, Merrill J, Looney R, Buyon J, Wallace D, Weisman M, et al.
Arthritis Res Ther
. 2015 Aug;
17:215.
PMID: 26290435
Introduction: Blisibimod is a potent B cell-activating factor (BAFF) antagonist that binds to both cell membrane-expressed and soluble BAFF. The goal of these first-in-human studies was to characterize the safety,...